{"disease":{"id":"solid-tumor-malignancy","name":"solid tumor malignancy"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04496375","title":"An Evaluation of Patients Access to Their Electronic Medical Records Via the IPC Connect Application","phase":"","overall_status":"UNKNOWN","enrollment_count":8000,"lead_sponsor_name":"Institut Paoli-Calmettes","has_results":false},{"nct_id":"NCT05695638","title":"Proseq Cancer: Genomic Profiling in Patients With Incurable Cancer in Search for Targeted Treatment","phase":"","overall_status":"RECRUITING","enrollment_count":3000,"lead_sponsor_name":"Morten Ladekarl","has_results":false},{"nct_id":"NCT06665776","title":"HLA-A*02:01 Allele Frequency and the NY-ESO-1 Expression Status in Cancer Patients in Taiwan","phase":"","overall_status":"RECRUITING","enrollment_count":1200,"lead_sponsor_name":"PharmaEssentia","has_results":false},{"nct_id":"NCT05600933","title":"Prospective Procurement of Tumor Tissue to Identify Novel Therapeutic Targets and Study the Tumor Microenvironment","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":1200,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT02834013","title":"Nivolumab and Ipilimumab in Treating Patients With Rare Tumors","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":818,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT01231347","title":"QUILT-2.014: Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":800,"lead_sponsor_name":"NantCell, Inc.","has_results":true},{"nct_id":"NCT06090513","title":"Molecular Services and EMR-Lab Integration Application (ELIA) for Reducing Healthcare Disparities in Cancer Patients","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":300,"lead_sponsor_name":"Bien-Willner Physicians Group PA","has_results":false},{"nct_id":"NCT05159245","title":"The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":250,"lead_sponsor_name":"Helsinki University Central Hospital","has_results":false},{"nct_id":"NCT06989489","title":"Implementation of an Oral Chemotherapy Adherence Intervention","phase":"NA","overall_status":"RECRUITING","enrollment_count":160,"lead_sponsor_name":"UNC Lineberger Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT06985368","title":"A Clinical Trial of SIBP-A18 Injection in the Treatment of Advanced Malignant Solid Tumor Patients","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":156,"lead_sponsor_name":"Shanghai Institute Of Biological Products","has_results":false},{"nct_id":"NCT04826458","title":"Clinical Study Comparing Different Strategies to Increase Adherence to Oral Therapies in Oncohematology","phase":"NA","overall_status":"COMPLETED","enrollment_count":124,"lead_sponsor_name":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","has_results":false},{"nct_id":"NCT02712905","title":"An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":116,"lead_sponsor_name":"Incyte Corporation","has_results":true},{"nct_id":"NCT06615193","title":"A Study of HDM2005 in Patients With Relapsed/Refractory B-cell Lymphoma and Advanced Solid Tumor","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":111,"lead_sponsor_name":"Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT03822117","title":"Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":111,"lead_sponsor_name":"Incyte Corporation","has_results":true},{"nct_id":"NCT02041416","title":"Technology to Assess Vulnerable Older Adults With Cancer and Their Caregivers","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":100,"lead_sponsor_name":"City of Hope Medical Center","has_results":false},{"nct_id":"NCT06106360","title":"A Pilot Prospective Clinical Trial Using Remote Monitoring for Cancer Patients Undergoing Outpatient Chemotherapy","phase":"","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Inova Health Care Services","has_results":false},{"nct_id":"NCT06225856","title":"An Open-Label, Multicenter, Phase I Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of YY201 in Patients With Advanced Solid Tumors and Hematological Malignancies","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":96,"lead_sponsor_name":"Shanghai Yuyao Biotech Co., Ltd.","has_results":false},{"nct_id":"NCT02431260","title":"An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":69,"lead_sponsor_name":"Incyte Corporation","has_results":true},{"nct_id":"NCT04260529","title":"CyPep-1 Injections in Cancer Inducing Lymphocyte Infiltrate Accumulations","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"Cytovation AS","has_results":true},{"nct_id":"NCT04552288","title":"Study of Benralizumab in People With Skin Side Effects Caused by Cancer Therapies","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":51,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":true},{"nct_id":"NCT03560882","title":"A Pilot Trial of Atorvastatin in Tumor Protein 53 (p53) -Mutant and p53 Wild-Type Malignancies","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":50,"lead_sponsor_name":"Joaquina Baranda","has_results":false},{"nct_id":"NCT02492789","title":"A Trial to Evaluate Safety and Tolerability of INCSHR01210 in Cancer Patients","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":49,"lead_sponsor_name":"Atridia Pty Ltd.","has_results":false},{"nct_id":"NCT04347226","title":"Anti-Interleukin-8 (Anti-IL-8) for Patients With COVID-19","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":43,"lead_sponsor_name":"Columbia University","has_results":true},{"nct_id":"NCT06528249","title":"Safety, Tolerability and Preliminary Efficacy of Erythrocyte-αPD-1 Conjugate in Patients With Advanced Malignancies","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":39,"lead_sponsor_name":"Zhejiang Provincial People's Hospital","has_results":false},{"nct_id":"NCT04305249","title":"Safety and Preliminary Efficacy of ATG-017 Monotherapy or Combination Therapy With Nivolumab in Advanced Solid Tumors and Hematological Malignancies","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":36,"lead_sponsor_name":"Antengene Therapeutics Limited","has_results":false},{"nct_id":"NCT05391022","title":"Study Evaluating Food Effect and QTc in Patients With Advanced Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":35,"lead_sponsor_name":"Constellation Pharmaceuticals","has_results":false},{"nct_id":"NCT04944888","title":"GSL Synthetase Inhibitor in Combination With Immune Checkpoint Inhibitor in Previously Treated Blood and Solid Tumor","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":31,"lead_sponsor_name":"Chinese PLA General Hospital","has_results":false},{"nct_id":"NCT04082910","title":"Metoprolol Treatment for Cytokine Release Syndrome in Patients Treated With Chimeric Antigen Receptor T Cells","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"Chinese PLA General Hospital","has_results":false},{"nct_id":"NCT05707325","title":"Safety, Tolerability and Preliminary Efficacy of Engineered Red Blood Cell in Patients With Advanced Malignancies","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Westlake Therapeutics","has_results":false},{"nct_id":"NCT06566209","title":"FDG-PET as an Imaging Modality to Diagnose and Risk Stratify Subclinical, Imaging Negative Ici-Myocarditis","phase":"","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT05200273","title":"A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK114","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"Akeso","has_results":false},{"nct_id":"NCT05164016","title":"Evaluating Immune Response to COVID-19 Vaccines in Patients With Cancer, Transplant or Cellular Therapy Recipients","phase":"","overall_status":"COMPLETED","enrollment_count":21,"lead_sponsor_name":"St. Jude Children's Research Hospital","has_results":false},{"nct_id":"NCT06753513","title":"Clinical Application of 99mTc-FDPH46 SPECT/CT Imaging in Malignant Solid Tumor: a Prospective Exploratory Study","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":20,"lead_sponsor_name":"Zhejiang University","has_results":false},{"nct_id":"NCT04886622","title":"A Study of DT2216 in Relapsed/Refractory Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"Dialectic Therapeutics, Inc","has_results":false},{"nct_id":"NCT04847050","title":"A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants With Solid Tumors on PD1/PDL1 Inhibitor Therapy","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":19,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT05501821","title":"Study of KBA1412 in Participants With Advanced Solid Malignant Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":16,"lead_sponsor_name":"Kling Biotherapeutics B.V.","has_results":false},{"nct_id":"NCT06630247","title":"A Dose-escalation, Dose-finding, and Expansion Study of XL495 in Participants With Locally Advanced or Metastatic Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":9,"lead_sponsor_name":"Exelixis","has_results":false}],"total":37},"guidelines":[],"source":"Drug Landscape verified database"}